Search Results
), lifetime phencyclidine (PCP) use (variable PCPFLAG; 0 = never used, 1 = ever used), lifetime 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) use (variable ECSFLAG for 2013–2014 and ECSTMOFLAG for 2015–2019; 0 = never used, 1 = ever used), and lifetime
(MDMA/ecstasy) use (variable ECSFLAG for 2013–2014 and ECSTMOFLAG for 2015–2019; 0 = never used, 1 = ever used), and lifetime inhalant use (variable INHFLAG for 2013–2014 and INHALFLAG for 2015–2019; 0 = never used, 1 = ever used). All covariates were
psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA) and ketamine for treating psychological disorders, psilocybin for the treatment of depression has the most extensive and robust empirical support. As with many mental disorders, depression
World Religions , 3 ( 2019 ), 81 – 103 . http://doi.org/10.1556/2054.2019.012 . Roberts T. (Ed.). ( 2020 ). Psychedelics and spirituality: The sacred use of LSD, psilocybin, and MDMA for human transformation . Rochester, VT : Park Street Press
, 2021 , 39:53). This confidence in the notion that psychedelics will radically minimize interpersonal harms reappears in another frequent slogan: “I believe that fully globalized access to MDMA-assisted therapy can lead to a world of net-zero trauma by
maltreatment ( Healy, Lee, & D’Andrea, 2021 ). This finding suggests that psychedelics may reduce the impact of a history of adverse childhood experiences (ACEs) on distress in adulthood. In addition, a randomized, double-blind, placebo-controlled study of MDMA
findings are consistent with prior studies showing that MDMA, a serotonergic psychedelic, has been shown to produce significant PTSD symptom reduction ( Ot’alora G et al., 2018 ). Additionally, animal studies have shown that ibogaine was effective in
The effect of group-administered psilocybin on psychological flexibility and outcomes Research on the efficacy of psychedelic-assisted therapy (PAT) has expanded rapidly in the last decade. The FDA has designated breakthrough therapy status for MDMA
therapies for psychiatric disorders: Psilocybin and MDMA . The Lancet Psychiatry , 3 , 481 – 488 . https://doi.org/10.1016/s2215-0366(15)00576-3 . Moreno , F. A. , Wiegand , C. B. , Taitano , E. K. , & Delgado , P. L. ( 2006 ). Safety
enedioxy methamphetamine (MDMA) for synergistic MDMA effects is well known and referred to as “candyflipping” ( Chary, Yi, & Manini, 2018 ; Schechter, 1998 ). However, combining LSD and other stimulants appears to be less common ( Licht et al., 2012 ). In the case of
